Thiazide or Thiazide-Like Diuretic
In a patient who develops cough on ACE inhibitors or ARBs and peripheral edema on calcium channel blockers, a thiazide or thiazide-like diuretic (such as chlorthalidone 12.5–25 mg daily or indapamide 1.5 mg daily) should be the next antihypertensive agent tried.
Rationale Based on Guidelines
Multiple international hypertension guidelines consistently identify four major first-line drug classes for hypertension: ACE inhibitors, ARBs, calcium channel blockers (CCBs), and thiazide/thiazide-like diuretics 1, 2, 3. Since you've already encountered intolerance to three of these classes, the logical next step is a thiazide diuretic.
The 2024 ESC guidelines explicitly state that thiazide/thiazide-like diuretics demonstrate a linear relationship between blood pressure reduction and cardiovascular event reduction, making them recommended first-line treatments 2. The 2017 ACC/AHA guidelines similarly position thiazides as primary agents with proven trial reduction of cardiovascular disease 3.
Why Not Other Options First?
Beta-Blockers Are Not Preferred Initial Therapy
The 2016 UK guidelines clearly state that beta-blockers are not a preferred initial therapy for hypertension 4. They should be reserved for specific compelling indications such as:
- Post-myocardial infarction
- Heart failure with reduced ejection fraction
- Angina
- Heart rate control needs
Without these specific indications, beta-blockers rank lower than thiazide diuretics 1, 4.
The Cough Issue with ACE/ARB
Your patient has already demonstrated intolerance to the renin-angiotensin system blockers. The ACC/AHA heart failure guidelines note that ACE inhibitor-induced cough occurs in 5-10% of white patients and up to 50% in Chinese patients 5. While ARBs cause less cough, research shows they still carry cough risk 6, 7. More importantly, you should not combine an ACE inhibitor with an ARB 4, 2—this is explicitly contraindicated in guidelines.
The Edema Problem with CCBs
Peripheral edema from CCBs is dose-related and common 3. While adding a renin-angiotensin system blocker can reduce CCB-associated edema by 38% 8, this strategy is not viable for your patient who cannot tolerate ACE inhibitors or ARBs due to cough.
Practical Implementation
Start with chlorthalidone 12.5–25 mg once daily (preferred over hydrochlorothiazide due to longer half-life and proven cardiovascular disease reduction in trials) 4, 3 or indapamide 1.5 mg modified-release once daily 4.
Monitoring Requirements
- Check serum electrolytes (sodium, potassium) and renal function before starting 4
- Recheck within 1 week of initiation 4
- Monitor for hyponatremia, hypokalemia, and uric acid elevation 3
- Use with caution if history of acute gout unless on uric acid-lowering therapy 3
If Blood Pressure Remains Uncontrolled
If the thiazide diuretic alone doesn't achieve target blood pressure, the 2024 ESC guidelines recommend a three-drug combination typically consisting of a RAS blocker + CCB + thiazide diuretic 2. However, given your patient's intolerances, you would need to consider:
- Adding a beta-blocker to the thiazide (if no contraindications) 1
- Spironolactone 25 mg daily as add-on therapy for resistant hypertension (Step 4 treatment) 4, 3—but monitor potassium closely
- Alpha-blocker or centrally acting agent as fourth-line options 4, 2
Common Pitfalls to Avoid
- Don't immediately jump to beta-blockers without trying a thiazide first—guidelines are clear that thiazides are preferred over beta-blockers for uncomplicated hypertension 4
- Don't rechallenge with another ACE inhibitor or ARB if cough was persistent and troublesome—the cough mechanism is class-related (bradykinin accumulation) 5
- Don't use conventional thiazides (bendroflumethiazide, hydrochlorothiazide) if initiating new therapy—prefer thiazide-like agents (chlorthalidone, indapamide) 4
- Monitor electrolytes carefully—thiazides can cause hypokalemia and hyponatremia, particularly in elderly patients 3